Cyclin D as a therapeutic target in cancer

[1]  Joshua E. Elias,et al.  A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers , 2011, Nature.

[2]  T. Hudson,et al.  Somatic variation and cancer: therapies lost in the mix , 2011, Human Genetics.

[3]  Edward S. Kim,et al.  Cotargeting Cyclin D1 Starts a New Chapter in Lung Cancer Prevention and Therapy , 2011, Cancer Prevention Research.

[4]  E. Dmitrovsky,et al.  Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models , 2011, Cancer Prevention Research.

[5]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[6]  K. Wilner,et al.  Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1) , 2011, British Journal of Cancer.

[7]  M. Schlissel,et al.  Forced Expression of Cyclin-Dependent Kinase 6 Confers Resistance of Pro-B Acute Lymphocytic Leukemia to Gleevec Treatment , 2011, Molecular and Cellular Biology.

[8]  M. Kitagawa,et al.  Coordinated regulation of differentiation and proliferation of embryonic cardiomyocytes by a jumonji (Jarid2)-cyclin D1 pathway , 2011, Development.

[9]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[10]  V. Velculescu,et al.  Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer , 2011, Clinical Cancer Research.

[11]  M. Socinski,et al.  Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Elsaleh,et al.  Alternative cyclin D1 splice forms differentially regulate the DNA damage response. , 2010, Cancer research.

[13]  M. Herlyn,et al.  Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. , 2010, Cancer cell.

[14]  H. Rui,et al.  RB-pathway disruption in breast cancer , 2010, Cell cycle.

[15]  H. Clevers,et al.  Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss. , 2010, Cancer research.

[16]  L. Chodosh,et al.  The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2 , 2010, Oncogene.

[17]  Y. Kuwahara,et al.  Acquired radioresistance of human tumor cells by DNA-PK/AKT/GSK3β-mediated cyclin D1 overexpression , 2010, Oncogene.

[18]  E. Knudsen,et al.  Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure , 2010, Oncogene.

[19]  M. Barbacid,et al.  A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. , 2010, Cancer cell.

[20]  Kwok-Kin Wong,et al.  Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. , 2010, The Journal of clinical investigation.

[21]  Yonghong Xiao,et al.  Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM , 2010, Proceedings of the National Academy of Sciences.

[22]  D. Berney,et al.  The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. , 2010, The American journal of pathology.

[23]  Xiaopei Huang,et al.  Role of Cdk4 in lymphocyte function and allergen response , 2010, Cell cycle.

[24]  R. Bosotti,et al.  Transcriptional Analysis of an E2F Gene Signature as a Biomarker of Activity of the Cyclin-Dependent Kinase Inhibitor PHA-793887 in Tumor and Skin Biopsies from a Phase I Clinical Study , 2010, Molecular Cancer Therapeutics.

[25]  P. Lienau,et al.  Abstract 3883: Pharmacologic profile of the oral novel pan-CDK inhibitor BAY 1000394 in chemosensitive and chemorefractory tumor models , 2010 .

[26]  M. Prados,et al.  Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. , 2010, Cancer research.

[27]  A. Troxel,et al.  Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome. , 2010, Anticancer research.

[28]  Chenguang Wang,et al.  Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells. , 2010, Cancer research.

[29]  S. Bao,et al.  Methylation of Ribosomal Protein S10 by Protein-arginine Methyltransferase 5 Regulates Ribosome Biogenesis* , 2010, The Journal of Biological Chemistry.

[30]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[31]  Clifford A. Meyer,et al.  Transcriptional role of cyclin D1 in development revealed by a genetic–proteomic screen , 2010, Nature.

[32]  P. Hinds,et al.  Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis. , 2010, Cancer cell.

[33]  Sinan Zhu,et al.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance , 2010, Clinical Medicine Insights. Oncology.

[34]  S. Sen,et al.  Cyclin D1b represses breast cancer cell growth by antagonizing the action of cyclin D1a on estrogen receptor alpha-mediated transcription. , 2009, International journal of oncology.

[35]  M. Stratton,et al.  A census of amplified and overexpressed human cancer genes , 2010, Nature Reviews Cancer.

[36]  P. Kaldis,et al.  Cdk2 and Cdk4 Regulate the Centrosome Cycle and Are Critical Mediators of Centrosome Amplification in p53-Null Cells , 2009, Molecular and Cellular Biology.

[37]  W. Gu,et al.  Suppression of cancer cell growth by promoting cyclin D1 degradation. , 2009, Molecular cell.

[38]  Shih-Yin Tsai,et al.  Emerging roles of E2Fs in cancer: an exit from cell cycle control , 2009, Nature Reviews Cancer.

[39]  J. Dering,et al.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.

[40]  H. Inoue,et al.  Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells , 2009, Molecular carcinogenesis.

[41]  E. Hanse,et al.  Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo , 2009, Cell cycle.

[42]  H. Rui,et al.  Cyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer , 2009, Clinical Cancer Research.

[43]  Robert L. Sutherland,et al.  Biological determinants of endocrine resistance in breast cancer , 2009, Nature Reviews Cancer.

[44]  James Rosinski,et al.  Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients , 2009, Molecular Cancer Therapeutics.

[45]  J. Diehl,et al.  Nuclear cyclin D1: An oncogenic driver in human cancer , 2009, Journal of cellular physiology.

[46]  T. Brunner,et al.  miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. , 2009, Cancer research.

[47]  A. Giordano,et al.  Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.

[48]  Gordon B Mills,et al.  Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer , 2009, Clinical Cancer Research.

[49]  H. Rui,et al.  Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome , 2009, Oncogene.

[50]  Rajiv Chopra,et al.  Crystal structure of human CDK4 in complex with a D-type cyclin , 2009, Proceedings of the National Academy of Sciences.

[51]  M. E. M. Noble,et al.  The structure of CDK4/cyclin D3 has implications for models of CDK activation , 2009, Proceedings of the National Academy of Sciences.

[52]  W. Steward,et al.  A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours , 2009, Cancer Chemotherapy and Pharmacology.

[53]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[54]  G. Hu,et al.  A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. , 2009, Cancer research.

[55]  K. Knudsen,et al.  Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer , 2008, Oncogene.

[56]  M. Wang,et al.  Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy , 2009, Leukemia.

[57]  Y. Mo,et al.  Systematic validation of predicted microRNAs for cyclin D1 , 2009, BMC Cancer.

[58]  J. Li,et al.  Cyclin D1 in low-dose radiation-induced adaptive resistance , 2008, Oncogene.

[59]  T. Mok,et al.  Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients. , 2008, Human pathology.

[60]  N. Munshi,et al.  RGB 286638, a Novel Multi-Targeted Small Molecule Inhibitor, Induces Multiple Myeloma (MM) Cell Death through Abrogation of CDKDependent and Independent Survival Mechanisms , 2008 .

[61]  Mauro Biffoni,et al.  The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities , 2008, Nature Medicine.

[62]  H. Ozçelik,et al.  Cyclin D1 Pro241Pro (CCND1-G870A) Polymorphism Is Associated with Increased Cancer Risk in Human Populations: A Meta-Analysis , 2008, Cancer Epidemiology Biomarkers & Prevention.

[63]  C. Bassing,et al.  Genotoxic Stress-Induced Cyclin D1 Phosphorylation and Proteolysis Are Required for Genomic Stability , 2008, Molecular and Cellular Biology.

[64]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[65]  K. Knudsen,et al.  Tailoring to RB: tumour suppressor status and therapeutic response , 2008, Nature Reviews Cancer.

[66]  Hong Wu,et al.  Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas , 2008, Molecular Cancer Therapeutics.

[67]  T. Tiganis,et al.  DNA replication stalling attenuates tyrosine kinase signaling to suppress S phase progression. , 2008, Cancer cell.

[68]  Gabriel Sanchez,et al.  Coupled alteration of transcription and splicing by a single oncogene: Boosting the effect on cyclin D1 activity , 2008, Cell cycle.

[69]  K. Kaestner,et al.  Distinct proliferative and transcriptional effects of the D-type cyclins in vivo , 2008, Cell cycle.

[70]  S. Chen‐Kiang,et al.  A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. , 2008, Cancer research.

[71]  A. Rustgi,et al.  Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer. , 2008, Cancer cell.

[72]  R. Greil,et al.  Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy , 2008, Clinical Cancer Research.

[73]  G. Prendergast,et al.  Alternate Cyclin D1 mRNA Splicing Modulates p27KIP1 Binding and Cell Migration* , 2008, Journal of Biological Chemistry.

[74]  James M. Roberts,et al.  CDK Inhibitors : Cell Cycle Regulators and Beyond , 2008 .

[75]  A. Friedman,et al.  Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation. , 2007, Blood.

[76]  Andrew R. Green,et al.  CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome , 2008, Breast Cancer Research and Treatment.

[77]  A. Rustgi,et al.  Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. , 2007, Genes & development.

[78]  E. Campo,et al.  Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics , 2007, Nature Reviews Cancer.

[79]  Anne-Marie Duchemin,et al.  Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. , 2007, Blood.

[80]  Hanzhou Wang,et al.  Cyclin D3/CDK11p58 Complex Is Involved in the Repression of Androgen Receptor , 2007, Molecular and Cellular Biology.

[81]  R. Berro,et al.  Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells , 2007, Oncogene.

[82]  P. Kaldis,et al.  Cell-specific responses to loss of cyclin-dependent kinases , 2007, Oncogene.

[83]  K. Wilner,et al.  A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991 , 2007 .

[84]  A. Tan,et al.  A phase I study of R547, a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs) , 2007 .

[85]  Adrian Wiestner,et al.  Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. , 2007, Blood.

[86]  J. Alao,et al.  Molecular Cancer BioMed Central Review The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention , 2007 .

[87]  A. Giordano,et al.  A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo , 2007, Oncogene.

[88]  K. Knudsen,et al.  Impact of differential cyclin D1 expression and localisation in prostate cancer , 2007, British Journal of Cancer.

[89]  Oliver Gautschi,et al.  Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. , 2007, Lung Cancer.

[90]  T. Shioda,et al.  Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression. , 2006, Cancer research.

[91]  A. Thompson,et al.  Cyclin D1 and breast cancer. , 2006, Breast.

[92]  E. Pérez-Payá,et al.  Identification of an Hexapeptide That Binds to a Surface Pocket in Cyclin A and Inhibits the Catalytic Activity of the Complex Cyclin-dependent Kinase 2-Cyclin A* , 2006, Journal of Biological Chemistry.

[93]  Qing Xiang,et al.  In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials , 2006, Molecular Cancer Therapeutics.

[94]  Paul J. Smith,et al.  Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents , 2006 .

[95]  M. Lisanti,et al.  Cyclin D1 induction of cellular migration requires p27(KIP1). , 2006, Cancer research.

[96]  J. Herman,et al.  Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1 , 2006, Oncogene.

[97]  G. Peters,et al.  Regulation of the INK4b–ARF–INK4a tumour suppressor locus: all for one or one for all , 2006, Nature Reviews Molecular Cell Biology.

[98]  D. Sabatini.  mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.

[99]  P. Nowell,et al.  Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. , 2006, Blood.

[100]  M. Monden,et al.  Antisense to Cyclin D1 Inhibits Vascular Endothelial Growth Factor–Stimulated Growth of Vascular Endothelial Cells: Implication of Tumor Vascularization , 2006, Clinical Cancer Research.

[101]  Wei Li,et al.  The role of cell cycle regulatory proteins in the pathogenesis of melanoma , 2006, Pathology.

[102]  Chenguang Wang,et al.  Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[103]  S. Ely,et al.  A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. , 2006, Cancer research.

[104]  A. Joe,et al.  Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.

[105]  Anping Li,et al.  Cyclin D1 Determines Mitochondrial Function InVivo , 2006, Molecular and Cellular Biology.

[106]  U. Luecking,et al.  Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709. , 2006, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[107]  F. Liu,et al.  Cyclin D1-Cdk4 Induce Runx2 Ubiquitination and Degradation* , 2006, Journal of Biological Chemistry.

[108]  Anping Li,et al.  Cyclin D1 Regulates Cellular Migration through the Inhibition of Thrombospondin 1 and ROCK Signaling , 2006, Molecular and Cellular Biology.

[109]  Robin L. Jones,et al.  Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis , 2006, Modern Pathology.

[110]  G. Shapiro,et al.  Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  C. Haiman,et al.  Cyclin D1: polymorphism, aberrant splicing and cancer risk , 2006, Oncogene.

[112]  F. Cavalli,et al.  Update on the molecular biology of mantle cell lymphoma , 2006, Hematological oncology.

[113]  J. Celestino,et al.  Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma , 2006, International Journal of Gynecologic Cancer.

[114]  C. Haiman,et al.  Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[115]  E. Musgrove.  Cyclins: Roles in mitogenic signaling and oncogenic transformation , 2006, Growth factors.

[116]  Yan Geng,et al.  Requirement for CDK4 kinase function in breast cancer. , 2006, Cancer cell.

[117]  Tiansen Li,et al.  Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. , 2006, Cancer cell.

[118]  Y. Xiong,et al.  Negative regulation of TSC1-TSC2 by mammalian D-type cyclins. , 2005, Cancer research.

[119]  Jacinto J. Regalado,et al.  Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma , 2005, International journal of experimental pathology.

[120]  E. Dmitrovsky,et al.  Bexarotene and erlotinib for aerodigestive tract cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  L. Fajas,et al.  Cyclin D3 Promotes Adipogenesis through Activation of Peroxisome Proliferator-Activated Receptor γ , 2005, Molecular and Cellular Biology.

[122]  C P Neal,et al.  Molecular prognostic markers in pancreatic cancer: a systematic review. , 2005, European journal of cancer.

[123]  P. L. Bergsagel,et al.  Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  H. Heng,et al.  Overexpression of Cyclin D1 Promotes Tumor Cell Growth and Confers Resistance to Cisplatin-Mediated Apoptosis in an Elastase-myc Transgene–Expressing Pancreatic Tumor Cell Line , 2005, Clinical Cancer Research.

[125]  Daniela S Krause,et al.  Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.

[126]  A. Papanikolaou,et al.  Cyclin D1 in breast cancer pathogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  Mahadev Rao,et al.  Cyclin D1 Inhibits Peroxisome Proliferator-activated Receptor γ-mediated Adipogenesis through Histone Deacetylase Recruitment* , 2005, Journal of Biological Chemistry.

[128]  M. Morris,et al.  Design of a Novel Class of Peptide Inhibitors of Cyclin-dependent Kinase/Cyclin Activation* , 2005, Journal of Biological Chemistry.

[129]  P. Hinds,et al.  Multiple Functions of D-Type Cyclins Can Antagonize pRb-Mediated Suppression of Proliferation , 2005, Cell cycle.

[130]  W. Lingle,et al.  Short Term Cyclin D1 Overexpression Induces Centrosome Amplification, Mitotic Spindle Abnormalities, and Aneuploidy* , 2005, Journal of Biological Chemistry.

[131]  L. Skoog,et al.  Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance , 2005, Breast Cancer Research and Treatment.

[132]  James M. Roberts,et al.  Regulation of the cytoskeleton: an oncogenic function for cdk inhibitors? , 2004, Nature Reviews Cancer.

[133]  Chenguang Wang,et al.  Minireview: Cyclin D1: normal and abnormal functions. , 2004, Endocrinology.

[134]  R. Sutherland,et al.  Deregulated Cyclin D1 Expression Is Associated with Decreased Efficacy of the Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cell Lines , 2004, Clinical Cancer Research.

[135]  James M. Roberts,et al.  Living with or without cyclins and cyclin-dependent kinases. , 2004, Genes & development.

[136]  D. Toncheva,et al.  Tissue Microarray Analysis of Cyclin D1 Gene Amplification and Gain in Colorectal Carcinomas , 2004, Tumor Biology.

[137]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[138]  K. Akashi,et al.  Mouse Development and Cell Proliferation in the Absence of D-Cyclins , 2004, Cell.

[139]  Pierre Dubus,et al.  Mammalian Cells Cycle without the D-Type Cyclin-Dependent Kinases Cdk4 and Cdk6 , 2004, Cell.

[140]  S. Steinberg,et al.  Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer , 2004, Clinical Cancer Research.

[141]  Fang Liu,et al.  Cyclin-dependent kinases regulate the antiproliferative function of Smads , 2004, Nature.

[142]  J. Cigudosa,et al.  Molecular alterations associated with cyclin d1 overexpression in endometrial cancer , 2004, International journal of cancer.

[143]  L. Rydén,et al.  Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients , 2004, British Journal of Cancer.

[144]  J. Lamb,et al.  The activities of cyclin D1 that drive tumorigenesis. , 2004, Trends in molecular medicine.

[145]  David N Louis,et al.  The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer. , 2004, The American journal of pathology.

[146]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[147]  A. Ferrando,et al.  Requirement for cyclin D3 in lymphocyte development and T cell leukemias. , 2003, Cancer cell.

[148]  J. Minna,et al.  Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[149]  J. Cigudosa,et al.  Cyclin D1 gene (CCND1) mutations in endometrial cancer , 2003, Oncogene.

[150]  T. Golub,et al.  A Mechanism of Cyclin D1 Action Encoded in the Patterns of Gene Expression in Human Cancer , 2003, Cell.

[151]  David Hardisson,et al.  Molecular pathogenesis of head and neck squamous cell carcinoma , 2003, European Archives of Oto-Rhino-Laryngology.

[152]  Amanda Y. Chan,et al.  Cyclin D1 governs adhesion and motility of macrophages. , 2003, Molecular Biology of the Cell.

[153]  R. Hruban,et al.  Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[154]  C. Chomienne,et al.  Cyclin D3 Is a Cofactor of Retinoic Acid Receptors, Modulating Their Activity in the Presence of Cellular Retinoic Acid-binding Protein II* , 2003, The Journal of Biological Chemistry.

[155]  L. Staudt,et al.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.

[156]  O. Coqueret.  Linking cyclins to transcriptional control. , 2002, Gene.

[157]  A. Lassar,et al.  Cyclin D-cdk4 activity modulates the subnuclear localization and interaction of MEF2 with SRC-family coactivators during skeletal muscle differentiation. , 2002, Genes & development.

[158]  Richard Simon,et al.  Initiating oncogenic event determines gene-expression patterns of human breast cancer models , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[159]  H. Ropers,et al.  Formation of higher-order nuclear Rad51 structures is functionally linked to p21 expression and protection from DNA damage-induced apoptosis. , 2002, Journal of cell science.

[160]  Y. Geng,et al.  Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.

[161]  O. Jänne,et al.  Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. , 2001, Molecular endocrinology.

[162]  S. Weitzman,et al.  Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. , 2001, Cancer research.

[163]  R. Bronson,et al.  Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[164]  D. W. Fry,et al.  Cell Cycle and Biochemical Effects of PD 0183812 A POTENT INHIBITOR OF THE CYCLIN D-DEPENDENT KINASES CDK4 AND CDK6* , 2001 .

[165]  W. Sellers,et al.  Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity , 2000, Oncogene.

[166]  J. McKay,et al.  Cyclin D1 protein expression and gene polymorphism in colorectal cancer , 2000, International journal of cancer.

[167]  A H Calvert,et al.  Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. , 2000, Journal of medicinal chemistry.

[168]  Y. Yarden,et al.  Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway , 2000, Molecular and Cellular Biology.

[169]  K. Branigan,et al.  Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells , 1999, British Journal of Cancer.

[170]  P. Pandolfi,et al.  Targeted Disruption of CDK4 Delays Cell Cycle Entry with Enhanced p27Kip1 Activity , 1999, Molecular and Cellular Biology.

[171]  R. Sutherland,et al.  Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[172]  R. Blamey,et al.  Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[173]  M. Korc,et al.  Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. , 1999, Cancer research.

[174]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[175]  W. Cavenee,et al.  D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. , 1999, Cancer research.

[176]  M. Ewen,et al.  P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[177]  D. Germain,et al.  Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer , 1999, Oncogene.

[178]  R. Buckle,et al.  Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. , 1998, Genes & development.

[179]  Robert L Sutherland,et al.  Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells , 1998, Oncogene.

[180]  R. Sutherland,et al.  Differential Phosphorylation of T-47D Human Breast Cancer Cell Substrates by D1-, D3-, E-, and A-type Cyclin-CDK Complexes* , 1997, The Journal of Biological Chemistry.

[181]  M. Ewen,et al.  Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4 , 1997, Molecular and cellular biology.

[182]  R. Bernards,et al.  CDK-Independent Activation of Estrogen Receptor by Cyclin D1 , 1997, Cell.

[183]  C. Smythe,et al.  Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1 , 1997, Current Biology.

[184]  W. Sellers,et al.  Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors , 1996, Molecular and cellular biology.

[185]  J. Bartek,et al.  Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity , 1995, Molecular and cellular biology.

[186]  Emma Lees,et al.  Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice , 1994, Nature.

[187]  J. Bartek,et al.  DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1 , 1994, The Journal of cell biology.

[188]  E. Harlow,et al.  Identification of G1 kinase activity for cdk6, a novel cyclin D partner , 1994, Molecular and cellular biology.

[189]  Steven K. Hanks,et al.  Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins , 1992, Cell.